CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer. Hsieh CC, Hsu SH, Lin CY, Liaw HJ, et al. Br J Cancer 2022 Aug 23. pii: 10.1038/s41416-022-01946.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hsieh CC, Hsu SH, Lin CY, Liaw HJ, et al. CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer. Br J Cancer 2022 Aug 23. pii: 10.1038/s41416-022-01946.
PMID: 35999268